Extraperitoneal Open Radical Cystectomy: A New Standard in Frail Patients with Muscle-Invasive Bladder Cancer?

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101563282 Publication Model: Electronic Cited Medium: Print ISSN: 2039-7275 (Print) Linking ISSN: 20397275 NLM ISO Abbreviation: Clin Pract Subsets: PubMed not MEDLINE

Publication: 2021- : Basel, Switzerland : MDPI
Original Publication: Pavia : PAGEPress

Background/Objectives : Radical cystectomy (RC) represents one of the most complex and morbid surgical procedures in the field of Urology. Extraperitoneal open RC has emerged as an alternative to the traditional transperitoneal approach for the treatment of muscle-invasive bladder cancer. Frailty is one of the most important risk factors for perioperative morbidity and mortality, and this category of patients can benefit the most from the extraperitoneal approach. The purpose of this study was to evaluate the feasibility and the safety of extraperitoneal open RC in our experience; Methods : We retrospectively collected the data of 75 frail patients who underwent an extraperitoneal open RC, performed by a single experienced surgeon. We assessed their frailty status using the simplified frailty index (sFI). We recorded data regarding general characteristics, intraoperative, pathological, and postoperative complications, and mortality (within 90 days); Results: We analyzed 61 males and 14 females with an sFI equal to or higher than 3. The median age was 77 years. Fifty-one patients had an ASA score of 3 or more. Sixty procedures were with radical intention, while fifteen were palliative. Cutaneous ureterostomy was performed in 70 cases and extraperitonized ileal conduit in five cases. The median operative time was 150 min. The median blood loss was 400 mL. The median time to flatus was 2 days. The median postoperative stay was 7 days. Thirteen patients had Clavien-Dindo III or IV complications. Two patients died in first 90 days postoperatively; Conclusions : The extraperitoneal open RC in frail patients was demonstrated to be a feasible and safe alternative approach in definitive treatment or a palliative setting in our experience.

Eur Urol Focus. 2019 Jul;5(4):658-663. (PMID: 29366857)
J Urol. 2024 Jul;212(1):3-10. (PMID: 38661067)
Eur Urol. 2024 Jan;85(1):17-31. (PMID: 37858453)
Syst Rev. 2017 Aug 2;6(1):150. (PMID: 28768530)
BJU Int. 2020 Sep;126(3):388-395. (PMID: 32512649)
Eur Urol. 2015 Mar;67(3):376-401. (PMID: 25560798)
Eur Urol. 2009 Jan;55(1):164-74. (PMID: 18675501)
Eur Urol. 2017 Jan;71(1):96-108. (PMID: 27370177)
Sci Rep. 2018 Jan 18;8(1):1129. (PMID: 29348548)
PLoS One. 2023 Nov 30;18(11):e0294809. (PMID: 38032964)
Clin Genitourin Cancer. 2019 Oct;17(5):402-407. (PMID: 31402279)
Eur Urol. 2013 Feb;63(2):234-41. (PMID: 22877502)
World J Urol. 2010 Aug;28(4):457-63. (PMID: 19777243)
Urol J. 2020 Aug 22;18(5):519-524. (PMID: 32827149)
J Urol. 1999 Feb;161(2):545-8. (PMID: 9915445)
Scand J Urol. 2014 Aug;48(4):334-40. (PMID: 24844275)
Ann Surg Oncol. 2023 Sep;30(9):5932-5941. (PMID: 37344747)
Antibiotics (Basel). 2022 Feb 10;11(2):. (PMID: 35203832)
Ann Surg. 2009 Sep;250(3):449-55. (PMID: 19730176)
Urol Clin North Am. 2015 May;42(2):169-80, vii. (PMID: 25882559)
Eur Urol. 2020 Dec;78(6):893-906. (PMID: 32972792)
Eur Urol. 2011 Feb;59(2):204-10. (PMID: 21056535)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Eur Urol. 2022 Jan;81(1):75-94. (PMID: 34511303)
World J Surg Oncol. 2022 Apr 23;20(1):130. (PMID: 35459251)
J Glob Health. 2023 Sep 15;13:04109. (PMID: 37712386)
Ann Surg. 2004 Aug;240(2):205-13. (PMID: 15273542)
Transl Androl Urol. 2020 Dec;9(6):3073-3081. (PMID: 33457280)
Int Braz J Urol. 2018 Mar-Apr;44(2):296-303. (PMID: 29219280)
Int Urol Nephrol. 2011 Sep;43(3):663-7. (PMID: 21110093)

Keywords: bladder cancer; extraperitoneal open radical cystectomy; frailty; reperitonization

Date Created: 20241125 Latest Revision: 20241211

20250114

PMC11627156

10.3390/clinpract14060201

39585029